The impact of blinding on the results of a randomized, placebo–controlled multiple sclerosis clinical trial

Neurology

Volumn 44, Issue 1, 1994, Pages 16-20

  Noseworthy, J H ^a,b   Ebers, G C ^b   Vandervoort, M K ^b   Farquhar, R E ^c   Yetisir, E ^d   Roberts, R ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO; PREDNISONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; PHYSICIAN; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE;

CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; HUMANS; MULTIPLE SCLEROSIS; PHYSICIANS; PLACEBOS; PLASMA EXCHANGE; PREDNISONE; SINGLE-BLIND METHOD;

EID: 0028091401     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.44.1.16     Document Type: Article

References (16)

1. Mosteller F, Gilbert JP, McPeek B. Reporting standards and research strategies for controlled trials: agenda for the editor. Controlled Clin Trials 1980;1:37-58.
2. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981;2:31-49.
3. Der Simonian R, Charette LJ, McPeek B, Mosteller F. Reporting methods in clinical trials. N Engl J Med 1982;306:1332-1337.
4. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446.
5. Noseworthy JH, Vandervoort MK, Penman M, et al. Cyclophosphamide and plasma exchange in multiple sclerosis [letter]. Lancet 1991;337:1540-1541.
6. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
7. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35:312-319.
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;12:227-231.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
10. Breslow NE. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970;57:579-594.
11. Ney PG, Collins C, Spensor C. Double blind: double talk or are there ways to do better research? Med Hypotheses 1986;21:119-126.
12. The IFNB Multiple Sclerosis Study Group. Interferon beta- lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
13. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-918.
14. Kramer MS, Shapiro SH. Scientific challenges in the application of randomized trials. JAMA 1984;252:2739-2745.
15. Morgan PP. Randomized clinical trials need to be more clinical. JAMA 1985;253:1782-1783.
16. Moscucci M, Byrne L, Weintraub M, Cox C. Blinding, unblinding, and the placebo effect: an analysis of patients’ guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther 1987;41:259-265.